Immunovant, Inc. (IMVT) [Rocket]

In millions, except per share items	Mar-31-22	Mar-31-21	Mar-31-20	Mar-31-19
	10-K	10-K	10-K	10-K
Operating expenses:
Research and development	101.8	68.6	47.9	25.7
General and administrative	54.2	39.5	18.2	2.7
Total operating expenses	156.0	108.1	66.1	28.4
Other income	-0.8	0.3	0.4	-0.2
Loss before provision (benefit) for income taxes	-156.8	-107.8
Provision (benefit) for income taxes	-0.1	-0.4	0.1	0.0
Net loss	-156.7	-107.4	-66.4	-28.6

Net loss per common share - basic (in dollars per share)	($1.43)	($1.22)	($1.54)	($1.29)
Net loss per common share - diluted (in dollars per share)	($1.43)	($1.22)	($1.54)	($1.29)

Weighted-average common shares outstanding – basic (in shares)	109.7	87.8	43.2	22.2
Weighted-average common shares outstanding – diluted (in shares)	109.7	87.8